Takara Bio Inc.
Basic information
- Head office
- 4-38, Higashi-nishi 7-chome, Kusatsu City, Shiga Prefecture, Japan
- Chief executive
- Takeshi Miyamura
- Capital
- 14,965,828,496 (149 100 million)
- Employees (non-consolidated)
- 764 people
- Employees (consolidated)
- 1,743 people
- Start date
- 2002-04-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| DSS Takara Bio India Pvt. Ltd. | ||||||||
| Baori Medical Biotechnology (Beijing) Co., Ltd. | ||||||||
| DSS Imagetech Pvt. Ltd. | ||||||||
| Takara Bio Europe AB | ||||||||
|
|
||||||||
|
|
||||||||
|
|
Network
History
Released Japan's first domestically produced genetic engineering research reagent "restriction enzymes": Commenced bio business![]()
Established Takara Bio Engineering (Dalian) Co., Ltd. in Dalian, China, for manufacturing bio research reagents![]()
Established Dragon Genomics Co., Ltd.: Fully entered gene analysis services (absorbed by Takara Bio in 2002)![]()
Takara Brewery Co., Ltd. spun off: transitioned to holding structure and renamed to Takara Holdings Co., Ltd.; established Takara Brewery Co., Ltd. and Takara Bio Inc.![]()
Acquired management rights of Clontech Laboratories, Inc. (now Takara Bio USA, Inc.) in the United States![]()
Established Kinoshita Center Kinmu Co., Ltd. subsidiary in Okinawa Prefecture (transferred to Yuki Kuni Maitake Co., Ltd. in 2019)![]()
Acquired all shares of Cellectis AB in Yotebori City, Sweden, making it a subsidiary and renamed it Takara Bio Europe AB.![]()
Completed the Gene and Cell Processing Center in Kusatsu City, Shiga Prefecture: Commenced full‑scale CDMO operations providing development and manufacturing support services for regenerative medicine products and gene therapies.![]()
Completed a new headquarters building in Kusatsu City, Shiga Prefecture, and relocated headquarters functions there.![]()
Subsidiary Takara Bio USA Holdings, Inc. acquired all shares of Rubicon Genomics, Inc., and subsequently merged into Takara Bio USA, Inc.![]()
Subsidiary Takara Bio USA Holdings, Inc. acquired all shares of WaferGen Bio‑systems, Inc., and subsequently merged into Takara Bio USA, Inc.![]()
The NY‑ESO‑1/siTCR gene therapy for synovial sarcoma (development code: TBI‑1301) was designated as a subject item under the Ministry of Health, Labour and Welfare's "Accelerated Review Designation System."![]()
The NY‑ESO‑1/siTCR gene therapy (development code: TBI‑1301) was designated as a regenerative medicine product for rare diseases.![]()
Changed listing from the First Section to the Prime Market of the Tokyo Stock Exchange due to a review of market classifications.![]()
News
There is no news.
Public records
National Tax Agency basic information1160001002490
- Trade name
- タカラバイオ株式会社
- Trade name (kana)
- タカラバイオ
- Name in English
- Corporation type
- 301
- Address
- 〒525-0058 滋賀県草津市野路東7丁目4番38号
- Postal code
- 5250058
- Prefecture code
- 25
- City code
- 206
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2025-05-12
- Change date
- 2025-05-01
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- 令和7年5月1日神戸市中央区港島南町六丁目3番5号ViSpot株式会社(4140001107685)を合併
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 71
- Correction type
- 0
- Trade name image ID
- Address image ID
- Sequence number
- 3825775
METI gBizINFO1160001002490
- Corporate number
- 1160001002490
- Trade name
- タカラバイオ株式会社
- Trade name (kana)
- タカラバイオ
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 滋賀県草津市野路東7丁目4番38号
- Postal code
- 5250058
- Prefecture
- 滋賀県
- Prefecture code
- 25
- City or district
- 草津市
- City code
- 206
- Street address
- 野路東7丁目4番38号
- Organisation type
- 301
- Processing type
- 71
- Correction type
- 0
- Status
- Representative
- 代表取締役社長 仲尾 功一
- Capital
- 14965000000
- Employees
- 800
- Employees (male)
- Employees (female)
- Business summary
- 研究用試薬、理化学機器の開発製造販売、再生医療等製品の開発製造支援サービス、遺伝子解析受託サービス、遺伝子治療の臨床開発
- Website URL
- http://www.takara-bio.co.jp/
- Year founded
- Business category
- E:製造業
- Date established
- 2002-04-01
- Unified government qualification - grade
- A|A|A|
- Unified government qualification - business items
- 122|129|202|207|217|218|219|221|222|229|303|304|315
- Update date
- 2025-05-12
- Key information
- 1160001002490